Connect with others who understand.

Sign up Log in
About myPBCteam
Powered By
Real members of myPBCteam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

My GI IS MOVING ME FROM Ocaliva To Seladelpar.. Because FDA Says Former Is Less Effective. Anybody Have Experience W This?

A myPBCteam Member asked a question đź’­
Ormond Beach, FL
October 22
•
Be the first to like/hug
A myPBCteam Member

That’s the rationale I heard. I’ll be curious to see how this new one does. Ocaliva brought my numbers into “normal” range…

October 25
A myPBCteam Member

The side effects look worse than the PBC disease itself. Why do they pick such horrible prescriptions for us. Its like we are the guineas! Doesnt itching usually mean allergic? Or its screwing with our bilirubin!

October 25
A myPBCteam Member

Switching from Ocaliva (Obeticholic Acid) to Seladelpar (Livdelzi) is a significant change in your treatment for primary biliary cholangitis (PBC). Here are some key points about both medications:

Ocaliva (Obeticholic Acid)
- Usage: Prescribed for adults who have not responded well to ursodeoxycholic acid (UDCA) or cannot Show Full Answer

Switching from Ocaliva (Obeticholic Acid) to Seladelpar (Livdelzi) is a significant change in your treatment for primary biliary cholangitis (PBC). Here are some key points about both medications:

Ocaliva (Obeticholic Acid)
- Usage: Prescribed for adults who have not responded well to ursodeoxycholic acid (UDCA) or cannot tolerate it.
- Mechanism: Decreases bile production and increases bile removal from the liver.
- Side Effects: Itching, tiredness, stomach pain, rash, joint pain, mouth and throat pain, dizziness, constipation, swelling in hands or feet, fast or irregular heartbeat, fever, changes in thyroid function, and eczema. Rare but serious side effects include liver deterioration, potentially leading to liver failure, transplants, or death.

Seladelpar (Livdelzi)
- Usage: Approved for treating PBC in adults, either in combination with UDCA for those who do not respond adequately to UDCA alone or as a monotherapy for those who cannot tolerate UDCA.
- Mechanism: Reduces alkaline phosphatase (ALP) levels, which are often elevated in PBC.
- Side Effects: Headache, abdominal pain, nausea, abdominal distension (bloating), and dizziness. Rare but serious side effects include fractures, liver test abnormalities, and biliary obstruction.

Considerations
- Effectiveness: Your GI may have recommended the switch based on the latest FDA guidance or clinical evidence suggesting that Seladelpar might be more effective for your specific condition.
- Monitoring: Both medications require careful monitoring by your healthcare provider to manage side effects and ensure effectiveness.

For more detailed information, you can visit the respective pages for [Ocaliva](https://www.myPBCteam.com/treatments/ocaliva) and [Livdelzi](https://www.myPBCteam.com/treatments/livdelzi). Always consult your healthcare provider for personalized advice.

October 22

Related content

View All

I Am Interested In Learning More About Seladelpar Which Has Been Recently Approved And Has Shown To Lower ALP Numbers. Has Anyone Tried It?

A myPBCteam Member asked a question đź’­
Peniel, FL

Iam Going To My Liver Specialist Tomorrow. Anyone Have Any Questions They Like For Me To Ask Her? I Hope It's Ok To Ask This.

A myPBCteam Member asked a question đź’­
Shreveport, LA

Does Anyone Have Experience With Using Seladelpar? I Just Started Taking It.

A myPBCteam Member asked a question đź’­
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data Policy and Privacy policies.Your privacy is our priority Lock Icon
Already a Member? Log in